Pfizer Venture Investments

• We can lead or join a syndicate of investors and will seek board representation commensurate with our investment
• Emphasis primarily on therapeutics (80%)
• Platforms, tools, and technologies with potential to transform drug discovery and development are also considered (20%)
• Approximately 20 percent of investments may be outside the U
• S
• Direct investing in private companies
• All stages possible, with focus on early stage
• Measured over long term
• $600M current capital commitment from Pfizer AUM $1
• 3B
• Up to $15M in first investment; reserved allocation for follow-on investments
• Investing as member of a syndicate
• Syndicate member must be located near company
• Potential for business relationship with Pfizer considered in investment criteria
• Can be transacted in parallel with investment or explored in the future
• Contribute capital and industry experience to help guide development and company growth
• Scientific advisory board participation when appropriate
• Board seats where appropriate
• Product rights not required

View a list of current and former companies that we've partnered with.

Our Team Looks Forward to Working with You Vice President, WWBD / Senior Managing Partner Executive Director, WWBD / Partner

Michael Baran, MBA, Ph.D.

Executive Director, WRDM / Partner Executive Director, WWBD and Partner at Pfizer Ventures Vice President, WRDM / Managing Partner

Marie-Claire Peakman, MRPharmS, Ph.D.

Executive Director, WRDM and Principal

• Research and Business Development Partnerships

Have an idea? Send us your opportunity for consideration.